Record Net Revenues of $31.7 million
Representing 17% Growth From the Prior Year
InfuSystem Holdings, Inc. (NYSE American: INFU)
(“InfuSystem” or the “Company”), a leading national health care
service provider, facilitating outpatient care for durable medical
equipment manufacturers and health care providers, today reported
financial results for the second quarter ended June 30, 2023.
2023 Second Quarter
Overview:
- Net revenues totaled $31.7 million, an increase of 17% vs.
prior year.
- Patient Services (formerly Integrated Therapy Services ("ITS"))
net revenue was $19.3 million, an increase of 12% vs. prior
year.
- Device Solutions (formerly Durable Medical Equipment Services
("DME Services")) net revenue was $12.4 million, an increase of 27%
vs. prior year.
- Gross profit was $16.4 million, an increase of 10% vs. prior
year.
- Gross margin was 51.8%, a decrease of 3.3% vs. prior year.
- Patient Services gross margin was 61.3%, an increase of 2.7%
vs. prior year.
- Device Solutions gross margin was 37.0%, a decrease of 11.8%
vs. prior year, up 2.5% sequentially.
- Net income increased $0.6 million to $0.4 million, or $0.02 per
diluted share vs. prior year net loss of $0.2 million, or $(0.01)
per diluted share.
- Adjusted earnings before interest, income taxes, depreciation,
and amortization (“Adjusted EBITDA”) (non-GAAP) was $5.8 million,
an increase of 4% vs. prior year, up 36% sequentially.
- Updating Net Revenue and Adjusted EBITDA guidance.
Management Discussion
Richard DiIorio, chief executive officer of InfuSystem, said, “I
am extremely pleased with the results of the second quarter, which
reflect the sixth consecutive quarter with record revenues. We
continue to demonstrate positive momentum against our plan by
delivering solid revenue growth of 17% for the second quarter. The
strength of our core businesses coupled with the execution of our
long-term growth strategy in biomedical services and wound care,
drove double-digit growth for both Patient Services (formerly ITS),
with revenue up 12%, and Device Solutions (formerly DME Services),
with revenue up 27%. Our current progress is a direct result of our
team’s hard work and commitment to providing high level service and
solutions to our patients and providers.”
“Additionally, with a focus on operational improvements, we had
sizable gains in profitability with Adjusted EBITDA margins up 4.2%
sequentially. We believe that we are having substantial success in
terms of executing our plan to deliver sustainable top-line growth
and improved profitability. Given our positive momentum, we now
believe our current year revenue growth to exceed the top end of
our previous range of 8% to 10%, and Adjusted EBITDA margin to be
between 17% and 18% for the year. Our unwavering commitment to help
people live healthier and longer lives provides the foundation to
deliver meaningful growth and drive shareholder value for our loyal
shareholders in the years to come,” concluded Mr. DiIorio.
2023 Second Quarter Financial Review
Net revenues for the quarter ended June 30, 2023 were $31.7
million, an increase of $4.7 million, or 17.4%, compared to $27.0
million for the quarter ended June 30, 2022. The increase included
higher net revenues for both the Patient Services and Device
Solutions segment.
Patient Services net revenue of $19.3 million increased $2.1
million, or 12.0%, during the second quarter of 2023 as compared to
the prior year period. This increase was primarily attributable to
additional treatment volume in Oncology, revenue from sales-type
leases of NPWT pumps, improved third party payer collections on
billings and higher prices. Net revenue in Oncology represented the
largest increase totaling $0.9 million, or 5.8%, compared to the
same prior year period. This was followed by an increase in revenue
for Wound Care which increased by $1.2 million, or 443%, compared
to the same prior year period, mainly due to an increase in sales
of equipment on sales-type leases, partially offset by lower
treatment volumes.
Device Solutions net revenue of $12.4 million (exclusive of
inter-segment revenues) increased $2.6 million, or 26.7%, during
the second quarter of 2023 as compared to the prior year period.
This increase included higher biomedical services revenue which
increased by $2.5 million, or 163%. The biomedical services revenue
included initial amounts of revenue from a new master services
agreement with a leading global healthcare technology and
diagnostic company that was launched in April 2022.
Gross profit of $16.4 million for the second quarter of 2023
increased $1.5 million, or 10.3%, from $14.9 million for the second
quarter of 2022. The increase was driven by the increase in net
revenue and was partially offset by a lower gross profit percentage
of net revenue ("gross margin"). Gross margin was 51.8% during the
second quarter of 2023 as compared to 55.1% during the prior year,
a decrease of 3.3%. Gross profit and gross margin increased in the
Patient Services segment, but were both lower in the Device
Solutions segment.
Patient Services gross profit was $11.8 million during the
second quarter of 2023, representing an increase of $1.7 million
compared to the prior year. The increase reflected the higher net
revenues and a higher gross margin, which increased from the prior
year by 2.7% to 61.3%. The increase in the gross margin reflected
lower pump disposal expenses, improved third party payer
collections on billings and improved coverage of fixed costs from
the higher net revenue. These improvements were partially offset by
unfavorable product mix favoring lower margin revenues. Pump
disposal expenses, which include retirements of damaged pumps and
reserves for missing pumps, decreased by $0.7 million during the
second quarter of 2023 as compared to the prior year period which
included an unusually high adjustment related to an updated
estimate of the volume of pumps considered missing based on pump
return data and physical inventories. The unfavorable gross margin
mix was mainly related to the increase in revenue related to NPWT
equipment leases which have a lower average gross margin than other
Patient Services revenue categories.
Device Solutions gross profit during the second quarter of 2023
was $4.6 million, representing a decrease of $0.2 million, or 4.0%,
compared to the prior year period. This decrease was due to a
decrease in the gross margin partially offset by higher net
revenues. The Device Solutions gross margin was 37.0% during the
current quarter, which was 11.8% lower than the prior year. This
decrease was due to an increase in labor costs related to an
increase in the number of biomedical technicians and other expenses
associated with the rapid on-boarding of the new master services
agreement. Some of the additional labor costs include training
activities and other labor expenses associated with building a
larger team in order to have the capacity required to support much
higher planned revenue volume. Over time, higher revenue levels are
expected to absorb a portion of the increased labor costs and
result in an improved gross margin. Other increased expenses
associated with the on-boarding ramp, which include increased
travel expenses and employee acquisitions costs, are expected to
decrease in the future. We currently estimate that the additional
expenses incurred during the second quarter of 2023 that will
either be absorbed or reduced totaled approximately $0.9
million.
Selling and marketing expenses were $3.0 million for the second
quarter of 2023, representing a decrease of $0.1 million, or 3.2%,
compared to the prior year period. Selling and marketing expenses
as a percentage of net revenues decreased to 9.4% compared to the
prior year period at 11.4%. This decrease reflected a reduction in
sales team members and improved coverage of fixed costs from the
higher net revenue. The selling and marketing expenses during these
periods consisted of sales personnel salaries, commissions and
associated fringe benefit and payroll-related items, marketing,
travel and entertainment and other miscellaneous expenses.
General and administrative (“G&A”) expenses for the second
quarter of 2023 were $12.0 million, an increase of 9.9% from $10.9
million for the second quarter of 2022. The increase of $1.1
million was due to a higher short-term incentive bonus accrued
expense totaling $0.5 million and increased expenses totaling $0.7
million associated with revenue volume growth which included the
cost of additional personnel, information technology and general
business expenses including inflationary increases. These amounts
were partially offset by lower stock-based compensation expense of
$0.1 million. G&A expenses as a percentage of net revenues for
the second quarter of 2023, decreased to 37.9% compared to 40.5%
for the prior year mainly reflecting improved net revenue leverage
over fixed costs.
Net income for the second quarter of 2023 was $0.4 million, or
$0.02 per diluted share, compared to a net loss of $0.2 million, or
$(0.01) per diluted share for the second quarter of 2022.
Adjusted EBITDA, a non-GAAP measure, for the second quarter of
2023 was $5.8 million, or 18.2% of net revenue, and increased by
$0.2 million, or 4.3%, compared to Adjusted EBITDA for the same
prior year quarter of $5.5 million, or 20.4% of prior period net
revenue.
Balance sheet, cash flows and liquidity
During the six-month period ended June 30, 2023, operating cash
flow decreased to $2.3 million, a $7.2 million or 76% decrease over
operating cash flow during the same prior year six-month period.
The decrease reflected lower operating margins during the year,
resulting from the additional biomedical labor expenses and higher
working capital levels. Capital expenditures during the first half
of 2023 included purchases of medical devices totaling $7.0 million
which was $0.3 million, or 5%, higher than the amount purchased
during the same prior year period.
On April 26, 2023, the Company amended the 2021 Credit Agreement
which features a $75 million revolving line of credit, does not
include any term indebtedness, and, as amended, matures on April
26, 2028. On May 11, 2023, the Company entered into a rate swap
agreement to fix the amount of interest expense for $20 million of
the outstanding borrowings under the loans with a termination date
matching the new credit agreement maturity date. Two interest rate
swaps existing prior to the amendment date were settled. As of June
30, 2023, available liquidity for the Company totaled $38.2 million
and consisted of $38.1 million in available borrowing capacity
under the revolving line of credit plus cash and cash equivalents
of $0.1 million. Net debt, a non-GAAP measure (calculated as total
debt of $36.1 million less cash and cash equivalents of $0.1
million) as of June 30, 2023 was $36.0 million representing an
increase of $3.0 million as compared to net debt of $33.0 million
as of December 31, 2022 (calculated as total debt of $33.2 million
less cash and cash equivalents of $0.2 million). Our ratio of
Adjusted EBITDA to net debt (non-GAAP) for the last four quarters
was 1.56 to 1.00 (calculated as net debt of $36.0 million divided
by Adjusted EBITDA of $21.8 million).
Full Year 2023 Guidance
InfuSystem is providing updated annual guidance for the full
year 2023 with net revenue growth estimated to be above the
previously stated range of 8% to 10% and Adjusted EBITDA margin
(non-GAAP) to be between 17% and 18% for the year.
The full year 2023 guidance reflects management’s current
expectation for operational performance, given the current market
conditions. This includes our best estimate of revenue and Adjusted
EBITDA. The Company and its businesses are subject to certain
risks, including those risk factors discussed in our most recent
annual report on Form 10-K for the year ended December 31, 2022,
filed on March 16, 2023. The financial guidance is subject to risks
and uncertainties applicable to all forward-looking statements as
described elsewhere in this press release.
Conference Call
The Company will conduct a conference call for all interested
investors on Thursday, August 3, 2023, at 9:00 a.m. Eastern Time to
discuss its second quarter 2023 financial results. The call will
include discussion of Company developments, forward-looking
statements and other material information about business and
financial matters.
To participate in this call, please dial (833) 366-1127 or (412)
902-6773, or listen via a live webcast, which is available in the
Investors section of the Company’s website at
https://ir.infusystem.com/. A replay of the call will be available
by visiting https://ir.infusystem.com/ for the next 90 days or by
calling (877) 344-7529 or (412) 317-0088, replay access code
9921883, through August 10, 2023.
Non-GAAP Measures
This press release contains information prepared in conformity
with GAAP as well as non-GAAP financial information. Non-GAAP
financial measures presented in this press release include EBITDA,
Adjusted EBITDA, Adjusted EBITDA Margin, net debt and Adjusted
EBITDA to net debt ratio. The Company believes that the non-GAAP
financial measures presented in this press release provide useful
information to the Company’s management, investors and other
interested parties about the Company’s operating performance
because they allow them to understand and compare the Company’s
operating results during the current periods to the prior year
periods in a more consistent manner. This non-GAAP information
should be considered by the reader in addition to, but not instead
of, the financial statements prepared in accordance with GAAP, and
similarly titled non-GAAP measures may be calculated differently by
other companies. The Company calculates those non-GAAP measures by
adjusting for non-recurring or non-core items that are not part of
the normal course of business. A reconciliation of those measures
to the most directly comparable GAAP measures is provided in the
accompanying schedule, titled "GAAP to Non-GAAP Reconciliation"
below. Future period non-GAAP guidance includes adjustments for
items not indicative of our core operations, which may include,
without limitation, items included in the accompanying schedule
below. Such adjustments may be affected by changes in ongoing
assumptions and judgments, as well as non-core, nonrecurring,
unusual or unanticipated changes, expenses or gains or other items
that may not directly correlate to the underlying performance of
our business operations. The exact amounts of these adjustments are
not currently determinable but may be significant. It is therefore
not practicable to provide the comparable GAAP measures or
reconcile this non-GAAP guidance to the most comparable GAAP
measures and, therefore, such comparable GAAP measures and
reconciliations are excluded from this release in reliance upon
applicable SEC staff guidance.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading
national health care service provider, facilitating outpatient care
for durable medical equipment manufacturers and health care
providers. INFU services are provided under a two-platform model.
The first platform is Patient Services (formerly Integrated Therapy
Services, or ITS), providing the last-mile solution for
clinic-to-home healthcare where the continuing treatment involves
complex durable medical equipment and services. The Patient
Services segment is comprised of Oncology, Pain Management, Wound
Therapy and Lymphedema businesses. The second platform, Device
Solutions (formerly Durable Medical Equipment Services, or DME
Services), supports the Patient Services platform and leverages
strong service orientation to win incremental business from its
direct payer clients. The Device Solutions segment is comprised of
direct payer rentals, pump and consumable sales, and biomedical
services and repair. Headquartered in Rochester Hills, Michigan,
the Company delivers local, field-based customer support and also
operates Centers of Excellence in Michigan, Kansas, California,
Massachusetts, Texas and Ontario, Canada.
Forward-Looking Statements
The financial results in this press release reflect preliminary
results, which are not final until the Company’s quarterly report
on Form 10-Q for the quarter year ended June 30, 2023 is filed. In
addition, certain statements contained in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, such as statements
relating to future actions, our share repurchase program and
capital allocation strategy, business plans, strategic
partnerships, growth initiatives, objectives and prospects, future
operating or financial performance, guidance and expected new
business relationships and the terms thereof (including estimated
potential revenue under new or existing contracts). The words
“believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“intend,” “should,” “plan,” “goal,” “expect,” “strategy,” “future,”
“likely,” variations of such words, and other similar expressions,
as they relate to the Company, are intended to identify
forward-looking statements. Forward-looking statements are subject
to factors, risks and uncertainties that could cause actual results
to differ materially, including, but not limited to, our ability to
successfully execute on our growth initiatives and strategic
partnerships, our ability to enter into definitive agreements for
the new business relationships on expected terms or at all, our
ability to generate estimated potential revenue amounts under new
or existing contracts, the uncertain impact of the COVID-19
pandemic, our dependence on estimates of collectible revenue,
potential litigation, changes in third-party reimbursement
processes, changes in law, global financial conditions and
recessionary risks, rising inflation and interest rates, supply
chain disruptions, systemic pressures in the banking sector,
including disruptions to credit markets, the Company's ability to
remediate its previously disclosed material weaknesses in internal
control over financial reporting, contributions from acquired
businesses or new business lines, products or services and other
risk factors disclosed in the Company’s most recent annual report
on Form 10-K and, to the extent applicable, quarterly reports on
Form 10-Q. Our strategic partnerships are subject to similar
factors, risks and uncertainties. All forward-looking statements
made in this press release speak only as of the date hereof. We do
not undertake any obligation to update any forward-looking
statements to reflect future events or circumstances, except as
required by law.
Additional information about InfuSystem Holdings, Inc. is
available at www.infusystem.com.
FINANCIAL TABLES
FOLLOW
INFUSYSTEM HOLDINGS, INC. AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
OPERATIONS
(UNAUDITED)
Three Months Ended June
30,
Six Months Ended June
30,
(in thousands, except share and per
share data)
2023
2022
2023
2022
Net revenues
$
31,735
$
27,042
$
62,105
$
53,805
Cost of revenues
15,293
12,141
30,123
23,537
Gross profit
16,442
14,901
31,982
30,268
Selling, general and administrative
expenses:
Provision for doubtful accounts
(67
)
(41
)
47
6
Amortization of intangibles
247
711
495
1,421
Selling and marketing
2,985
3,083
6,209
6,402
General and administrative
12,029
10,941
24,090
22,757
Total selling, general and
administrative
15,194
14,694
30,841
30,586
Operating income (loss)
1,248
207
1,141
(318
)
Other income (expense):
Interest expense
(620
)
(314
)
(1,104
)
(591
)
Other income (expense)
2
(30
)
(33
)
(58
)
Income (loss) before income taxes
630
(137
)
4
(967
)
(Provision for) benefit from income
taxes
(195
)
(27
)
107
435
Net income (loss)
$
435
$
(164
)
$
111
$
(532
)
Net income (loss) per share:
Basic
$
0.02
$
(0.01
)
$
0.01
$
(0.03
)
Diluted
$
0.02
$
(0.01
)
$
0.01
$
(0.03
)
Weighted average shares outstanding:
Basic
20,955,048
20,583,928
20,904,315
20,596,580
Diluted
21,600,346
20,583,928
21,565,667
20,596,580
INFUSYSTEM HOLDINGS, INC. AND
SUBSIDIARIES
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
SEGMENT REPORTING
(UNAUDITED)
Three Months Ended June
30,
Better/
(Worse)
(in thousands)
2023
2022
Net revenues:
Patient Services
$
19,319
$
17,244
$
2,075
Device Solutions (inclusive of
inter-segment revenues)
14,097
11,560
2,537
Less: elimination of inter-segment
revenues
(1,681
)
(1,762
)
81
Total
31,735
27,042
4,693
Gross profit (inclusive of certain
inter-segment allocations) (a):
Patient Services
11,845
10,113
1,732
Device Solutions
4,597
4,788
(191
)
Total
$
16,442
$
14,901
$
1,541
(a) Inter-segment allocations are for cleaning and repair
services performed on medical equipment.
Six Months Ended June
30,
Better/
(Worse)
(in thousands)
2023
2022
Net revenues:
Patient Services
$
38,093
$
33,885
$
4,208
Device Solutions (inclusive of
inter-segment revenues)
27,323
23,170
4,153
Less: elimination of inter-segment
revenues
(3,311
)
(3,250
)
(61
)
Total
62,105
53,805
8,300
Gross profit (inclusive of certain
inter-segment allocations) (a):
Patient Services
23,386
20,851
2,535
Device Solutions
8,596
9,417
(821
)
Total
$
31,982
$
30,268
$
1,714
(a) Inter-segment allocations are for cleaning and repair
services performed on medical equipment.
INFUSYSTEM HOLDINGS, INC. AND
SUBSIDIARIES
GAAP TO NON-GAAP
RECONCILIATION
(UNAUDITED)
NET INCOME (LOSS) TO EBITDA, ADJUSTED
EBITDA, NET INCOME (LOSS) MARGIN AND ADJUSTED EBITDA
MARGIN:
Three Months Ended June
30,
Six Months Ended June
30,
(in thousands)
2023
2022
2023
2022
GAAP net income (loss)
$
435
$
(164
)
$
111
$
(532
)
Adjustments:
Interest expense
620
314
1,104
591
Income tax provision (benefit)
195
27
(107
)
(435
)
Depreciation
2,846
2,689
5,801
5,395
Amortization
247
711
495
1,421
Non-GAAP EBITDA
$
4,343
$
3,577
$
7,404
$
6,440
Stock compensation costs
1,016
1,123
1,736
2,170
Medical equipment reserve and disposals
(1)
336
721
766
891
SOX readiness costs
—
70
—
110
Management reorganization/transition
costs
72
37
72
37
Certain other non-recurring costs
(6
)
(2
)
18
20
Non-GAAP Adjusted EBITDA
$
5,761
$
5,526
$
9,996
$
9,668
GAAP Net Revenues
$
31,735
$
27,042
$
62,105
$
53,805
Net Income (Loss) Margin (2)
1.4
%
(0.6
)%
0.2
%
(1.0
)%
Non-GAAP Adjusted EBITDA Margin
(3)
18.2
%
20.4
%
16.1
%
18.0
%
(1)
Amounts represent a non-cash expense
recorded to adjust the reserve for missing medical equipment and/or
the disposal of medical equipment and is being added back due to
its similarity to depreciation.
(2)
Net Income (Loss) Margin is defined as
GAAP Net Income (Loss) as a percentage of GAAP Net Revenues.
(3)
Non-GAAP Adjusted EBITDA Margin is defined
as Non-GAAP Adjusted EBITDA as a percentage of GAAP Net
Revenues.
INFUSYSTEM HOLDINGS, INC. AND
SUBSIDIARIES
CONSOLIDATED BALANCE
SHEETS
(UNAUDITED)
As of
(in thousands, except par value and
share data)
June 30, 2023
December 31,
2022
ASSETS
Current assets:
Cash and cash equivalents
$
134
$
165
Accounts receivable, net
18,870
16,871
Inventories
5,706
4,821
Other current assets
3,916
2,922
Total current assets
28,626
24,779
Medical equipment for sale or rental
3,206
2,790
Medical equipment in rental service, net
of accumulated depreciation
37,697
39,450
Property & equipment, net of
accumulated depreciation
4,303
4,385
Goodwill
3,710
3,710
Intangible assets, net
7,942
8,436
Operating lease right of use assets
4,392
4,168
Deferred income taxes
9,739
9,625
Derivative financial instruments
1,910
1,965
Other assets
1,224
80
Total assets
$
102,749
$
99,388
LIABILITIES AND STOCKHOLDERS’
EQUITY
Current liabilities:
Accounts payable
$
5,481
$
8,341
Current portion of long-term debt
—
—
Other current liabilities
7,386
6,126
Total current liabilities
12,867
14,467
Long-term debt, net of current portion
36,140
33,157
Operating lease liabilities, net of
current portion
3,786
3,761
Total liabilities
52,793
51,385
Stockholders’ equity:
Preferred stock, $0.0001 par value:
authorized 1,000,000 shares; none issued
—
—
Common stock, $0.0001 par value:
authorized 200,000,000 shares; 21,051,045 issued and outstanding as
of June 30, 2023 and 20,781,977 issued and outstanding as of
December 31, 2022
2
2
Additional paid-in capital
107,898
105,856
Accumulated other comprehensive income
1,442
1,489
Retained deficit
(59,386
)
(59,344
)
Total stockholders’ equity
49,956
48,003
Total liabilities and stockholders’
equity
$
102,749
$
99,388
INFUSYSTEM HOLDINGS, INC. AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
CASH FLOWS
(UNAUDITED)
Six Months Ended June
30,
(in
thousands)
2023
2022
OPERATING ACTIVITIES
Net income (loss)
$
111
$
(532
)
Adjustments to reconcile net income
(loss) to net cash provided by operating activities:
Provision for doubtful accounts
47
6
Depreciation
5,801
5,395
Loss on disposal of and reserve
adjustments for medical equipment
828
1,101
Gain on sale of medical equipment
(1,402
)
(883
)
Amortization of intangible assets
495
1,421
Amortization of deferred debt issuance
costs
78
37
Stock-based compensation
1,736
2,170
Deferred income taxes
(106
)
(435
)
Changes in assets -
(increase)/decrease:
Accounts receivable
(506
)
(924
)
Inventories
(885
)
(937
)
Other current assets
(994
)
599
Other assets
(1,719
)
(19
)
Changes in liabilities -
(decrease)/increase:
Accounts payable and other liabilities
(1,183
)
2,496
NET CASH PROVIDED BY OPERATING
ACTIVITIES
2,301
9,495
INVESTING ACTIVITIES
Purchase of medical equipment
(6,994
)
(6,669
)
Purchase of property and equipment
(494
)
(336
)
Proceeds from sale of medical equipment,
property and equipment
2,098
2,081
NET CASH USED IN INVESTING
ACTIVITIES
(5,390
)
(4,924
)
FINANCING ACTIVITIES
Principal payments on long-term debt
(29,451
)
(20,665
)
Cash proceeds from long-term debt
32,585
21,218
Debt issuance costs
(229
)
—
Cash payment of contingent
consideration
—
(750
)
Common stock repurchased as part of share
repurchase program
(153
)
(4,356
)
Common stock repurchased to satisfy
statutory withholding on employee stock-based compensation
plans
(523
)
(639
)
Cash proceeds from stock plans
829
746
NET CASH PROVIDED BY (USED IN)
FINANCING ACTIVITIES
3,058
(4,446
)
Net change in cash and cash
equivalents
(31
)
125
Cash and cash equivalents, beginning of
period
165
186
Cash and cash equivalents, end of
period
$
134
$
311
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230803952121/en/
Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC
602-889-9700
InfuSystems (AMEX:INFU)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
InfuSystems (AMEX:INFU)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024